Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma.

摘要: Objectives: Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the applicability of fibulin-3 plasma levels as response to treatment and its prognostic value progressive disease after in MM. The comparison with or addition soluble mesothelin-related peptides (SMRP) was also assessed. Materials Methods: included 78 MM patients treated at Institute Oncology Ljubljana between 2007 2011. samples obtained before various responses were measured enzyme-linked immunosorbent assay. Results: In treatment, not influenced by histopathological subtypes, tumor stages presence metastatic disease. Significantly higher found compared (U = 472.50, p 0.003), complete 42.00, 0.010), stable 542.00, 0.001). Patients exceeding 34.25 ng/ml had more than four times probability developing (OR 4.35, 95% CI 1.56–12.13). Additionally, above increased odds within 18 months 6.94, 0.99–48.55 OR 4.39, 1.63–11.81 respectively). Conclusions: Our findings suggest that SMRP could be helpful detecting progression